Condition
Torsades de Pointes
Total Trials
5
Recruiting
3
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Recruiting3
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07374263Recruiting
Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?
NCT07014735Not ApplicableRecruiting
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
NCT05521451Recruiting
Clinical Cohort Study - TRUST
NCT04000542Not ApplicableCompleted
Pharmacist Use of ECG to Inform Drug Therapy Decisions for Patients Receiving QT Prolonging Medications
NCT00839891Phase 1CompletedPrimary
A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers
Showing all 5 trials